A phase II study of arsenic trioxide in the treatment of relapsed and refractory low-grade lymphomas.

被引：0
|
作者：
Furman, RR [1 ]
Sirulnik, A [1 ]
Kamalu, OO [1 ]
Brenner, RB [1 ]
Paciucci, PA [1 ]
Gabrilove, JL [1 ]
Waxman, S [1 ]
机构：
[1] Mt Sinai Sch Med, Div Hematol & Oncol, New York, NY USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4758
引用
收藏
页码：304B / 304B
页数：1
相关论文
共 50 条
  • [21] Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study
    Chang, J. E.
    Voorhees, P. M.
    Kolesar, J. M.
    Ahuja, H. G.
    Sanchez, F. A.
    Rodriguez, G. A.
    Kim, K.
    Werndli, J.
    Bailey, H. H.
    Kahl, B. S.
    HEMATOLOGICAL ONCOLOGY, 2009, 27 (01) : 11 - 16
  • [22] THERAPY OF RELAPSED OR REFRACTORY LOW-GRADE FOLLICULAR LYMPHOMAS - FACTORS ASSOCIATED WITH COMPLETE REMISSION, SURVIVAL AND TIME TO TREATMENT FAILURE
    SPINOLO, JA
    CABANILLAS, F
    DIXON, DO
    KHORANA, SM
    MCLAUGHLIN, P
    VELASQUEZ, WS
    HAGEMEISTER, FB
    REDMAN, JR
    SWAN, F
    ANNALS OF ONCOLOGY, 1992, 3 (03) : 227 - 232
  • [23] TREATMENT APPROACHES TO THE LOW-GRADE LYMPHOMAS
    HORNING, SJ
    BLOOD, 1994, 83 (04) : 881 - 884
  • [24] Identification of genes those expression patterns distinguish low-grade lymphomas.
    Schmechel, SC
    Koehler, KM
    Yang, KH
    Sabath, DE
    BLOOD, 2002, 100 (11) : 314A - 315A
  • [25] High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas.: A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG)
    Weide, Rudolf
    Hess, Georg
    Koeppler, Hubert
    Heymanns, Jochen
    Thomalla, Joerg
    Aldaoud, Ali
    Losem, Christoph
    Schmitz, Stefan
    Haak, Ursula
    Huber, Christoph
    Unterhalt, Michael
    Hiddemann, Wolfgang
    Dreyling, Martin
    LEUKEMIA & LYMPHOMA, 2007, 48 (07) : 1299 - 1306
  • [26] A multicenter phase II study of combination treatment with melphalan, arsenic trioxide and vitamin C (MAC) for patients with relapsed or refractory multiple myeloma.
    Berenson, J
    Boccia, R
    Siegel, D
    Bozdech, M
    Bessudo, A
    Stadtmauer, E
    Pomeroy, JT
    Steis, R
    Flam, M
    Lutzky, J
    Jilani, S
    Volk, J
    Lindgren, T
    Moss, R
    Patel, R
    Ferreti, D
    Yeh, H
    Bevivino, S
    BLOOD, 2005, 106 (11) : 720A - 721A
  • [27] Phase II Study of Weekly Vinblastine in Recurrent or Refractory Pediatric Low-Grade Glioma
    Bouffet, Eric
    Jakacki, Regina
    Goldman, Stewart
    Hargrave, Darren
    Hawkins, Cynthia
    Shroff, Manohar
    Hukin, Juliette
    Bartels, Ute
    Foreman, Nicholas
    Kellie, Stewart
    Hilden, Joanne
    Etzl, Michael
    Wilson, Beverly
    Stephens, Derek
    Tabori, Uri
    Baruchel, Sylvain
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (12) : 1358 - 1363
  • [28] Phase II study of weekly vinblastine in recurrent/refractory pediatric low-grade gliomas
    Bouffet, Eric
    Jakacki, Regina
    Goldman, Stewart
    Hargrave, Darren
    Shroff, Manohar
    Hukin, Juliette
    Bartels, Ute
    Farley, Shannon
    Baruchel, Sylvain
    NEURO-ONCOLOGY, 2008, 10 (03) : 450 - 450
  • [29] A phase I/II trial of arsenic trioxide for relapsed and refractory-acute promyelocytic leukemia.
    Westervelt, P
    Adkins, D
    Brown, R
    Goodnough, LT
    Khoury, H
    Rush, C
    Lojka, T
    Miller, G
    DiPersio, JF
    BLOOD, 1998, 92 (10) : 219B - 219B
  • [30] GAMMA-INTERFERON IN THE TREATMENT OF LOW-GRADE LYMPHOMAS - A CRITICAL-REVIEW OF A PHASE-I-II-STUDY
    BERGMANN, L
    MITROU, PS
    TIMM, S
    ESSERS, U
    THEML, H
    KLIPPSTEIN, T
    GRIESINGER, F
    BLUT, 1987, 55 (04): : 243 - 243
12345